. Author manuscript; available in PMC: 2018 Jun 6.

Published in final edited form as: Gynecol Oncol. 2015 Nov 4;140(1):53–57. doi: 10.1016/j.ygyno.2015.11.004

Table 3.

Primary adjuvant chemotherapy regimens (N=39)

Chemotherapy Regimen	Number of Patients (%)
Cisplatin/carboplatin and etoposide (CE)	15 (38.5%)
Vinblastine, cisplatin, cyclophosphamide, bleomycin, doxorubicin and etoposide (VPCBAE)	10 (25.6%)
Carboplatin and paclitaxel	7 (17.9%)
Carboplatin, paclitaxel and bevacizumab	1 (2.6%)
Bleomycin, etoposide and cisplatin (BEP)	3 (7.7%)
Cisplatin, cyclophosphamide, doxorubicin and etoposide (CPAE)	1 (2.6%)
Cisplatin and etoposide followed by paclitaxel and carboplatin	1 (2.6%)
High dose chemotherapy (induction with carboplatin and paclitaxel × 3 cycles; mobilization with cyclophosphamide, etoposide and cisplatin × 1 cycle, followed by hyper-fractioned cyclophosphamide, doxorubicin and vincristine; followed by autologous stem cell transplant	1 (2.6%)